Jeffrey Glenn | Professor of Medicine and of Microbiology & Immunology
Stanford University

Jeffrey Glenn, Professor of Medicine and of Microbiology & Immunology, Stanford University

Jeffrey Glenn, M.D., Ph.D. is a Professor of Medicine (Division of Gastroenterology & Hepatology) and Microbiology & Immunology at Stanford University School of Medicine, and the Director of the Center for Hepatitis and Liver Tissue Engineering.  He also heads a research laboratory focused on studying molecular virology and the translation of that knowledge into novel antiviral strategies, as well as the development of new treatments for liver diseases and cancer. He leads ViRx@Stanford, which seeks to increase our collective antiviral tool kit to counter pandemics in a proactive, rather than reactive, fashion. He is the founder of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), co-founder of Riboscience LLC, and founder of I-Cubed Therapeutics, biotechnology companies developing several new classes of antiviral and anti-cancer drugs.

Glenn was born in Los Angeles, and grew up in Switzerland. He received his B.A. degree in Biochemistry and French Civilization from U.C. Berkeley from where he graduated summa cum laude.  He received his M.D. and Ph.D. in Biochemistry and Biophysics from U.C.S.F..  He trained in internal medicine at Stanford University where he completed specialty training in gastroenterology, and joined the faculty in 2000.

He is the principal investigator on multiple NIH grants, an inventor on numerous patents, an elected member of the American Society for Clinical Investigation, and a member of the FDA Antiviral Drugs Advisory Committee.

back to speakers

For conference programme and speaking opportunities:
Ellie Whitehead

ellie.whitehead@terrapinn.com

For sponsorship and exhibition opportunities:
Thomas Hall

thomas.hall@terrapinn.com